查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542954

全球低温治疗市场 - 2024-2031

Global Therapeutic Hypothermia Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

2023年，全球低温治疗市场达到2.88亿美元，预计2031年将达到4.5811亿美元，2024-2031年预测期间复合年增长率为6.1%。

治疗性低温或温度管理是一种积极的治疗方法，试图在特定的时间内达到并维持人的特定体温，以改善大脑血流停止一段时间后恢復期间的健康结果。这样做是为了降低血流不足导致组织损伤的风险。血流不良的时期可能是由于心臟骤停或血栓堵塞动脉（如中风）造成的。

低温治疗的有益效果也已被发现，并且透过与其他神经保护治疗相结合以及探索低温神经保护机制，在进一步提高低温治疗的益处方面取得了进展。

市场动态：

司机

神经系统和心血管疾病的盛行率不断增加

全球低温治疗市场的需求是由多种因素所驱动的。神经系统和心血管疾病盛行率的上升推动了市场的成长。例如，根据世界心臟联合会 2023 年 5 月 20 日发表的一篇文章，心血管疾病导致的死亡人数已从 1990 年的 1,210 万人增加到近年来的 2,050 万人。近年来，空气污染、烟草使用以及心血管疾病导致的死亡人数增加，导致高血压病例增加。

根据世界卫生组织网站2024年3月发布的一篇文章，神经系统疾病近年来增加了18%，超过三分之一的人患有神经系统疾病。据估计，全球总人口中有超过 30 亿人患有神经系统疾病。与女性相比，神经系统疾病会导致男性有更多的残疾和健康损失，但偏头痛或痴呆症等某些疾病对女性的影响尤其严重。

限制

与低温治疗相关的程序的复杂性和严格的监管要求等因素预计将阻碍市场的发展。

细分市场分析

全球低温治疗市场根据产品类型、应用、最终用户和地区进行细分。

神经科细分市场约占全球低温治疗市占率的43.4%

预计神经病学领域将在预测期内占据最大的市场份额。在该细分市场中，神经系统疾病盛行率的增加以及该细分市场中治疗性低温疗法使用的增加将推动该市场的发展。

根据 nih.gov 报告，低温治疗对心臟骤停患者和新生儿 HIE 患者均具有神经保护作用，并有望同样降低缺血性中风后的发病率和死亡率。事实上，一些临床前研究表明，在最近的一项荟萃分析中，在急性缺血性中风期间或短暂延迟后开始的轻度治疗性低温可减少梗塞面积并减轻功能障碍。除了这些研究之外，另一项研究也显示了可行性和耐受性，并制定了预防或减少通常清醒的中风患者颤抖的方案。

例如，在最近的一项多中心研究中，血管内冷却装置与重组组织纤溶酶原激活剂（rt-PA）联合用于急性中风患者。在这里，患者可以在症状出现后 0-6 小时内接受治疗，然后血管内冷却至 33°C，持续 24 小时。虽然研究的目的不是评估低温治疗的相对功效，但这种治疗方案似乎具有良好的耐受性，儘管降温患者中肺炎的发生率增加。一些缺血性中风的临床试验显示了低温治疗的良好效果。

市场地理分析

北美约占全球低温治疗市场份额的 47.2%

预计北美地区将在预测期内占据最大的市场份额。神经系统和心血管疾病的发生率不断上升，人们对低温治疗的好处的认识不断提高，以及该地区主要参与者的存在，都有助于推动市场发展。

例如，根据泛美卫生组织 (PAHO) 2024 年 3 月发布的一篇文章，美国已有 5,33,172 人死于各种神经系统疾病和病症。在这 5,33,172 例死亡中，男性 2,13,129 例，女性 3,20,043 例。在美国总人口中，每 10 万人中有 32.9 人死亡。在男性人口中，每10万人中有33.1人死亡，在女性人口中，每10万人中有32.2人死亡。

此外，根据 cdc.gov 2024 年 5 月发布的一篇文章，心血管疾病是美国人口死亡的主要原因。每 33 秒就有 1 人因心血管疾病死亡。每 5 人死亡就有 1 人死于心血管疾病。神经系统和心血管疾病盛行率的增加是主要驱动因素，北美地区占据了最大的市场份额。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 神经系统和心血管疾病的盛行率不断增加
      • 技术进步
      • 提高对低温治疗益处的认识
    • 限制
      • 手术中涉及的併发症
      • 严格的监管要求
  • 机会
  • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 未满足的需求
  • PESTEL分析
  • 专利分析
  • SWOT分析

第 6 章：依产品类型

  • 表面冷却包
  • 表面式热交换装置
  • 表面冷却头盔
  • 导管技术
  • 冷输液
  • 其他的

第 7 章：按申请

  • 神经病学
  • 心臟病学
  • 新生儿护理

第 8 章：最终用户

  • 医院
  • 专科诊所
  • 救护车和紧急医疗服务
  • 学术及研究机构
  • 其他的

第 9 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 和年成长分析（%），按配销通路
      • 德国
      • 英国
      • 法国
      • 义大利
      • 西班牙
      • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Asahi Kasei Corporation
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Becton Dickinson and Company
  • Shenzhen Comen Medical Instruments Co.
  • Terumo Cardiovascular Systems Co.
  • Phoenix Medical Systems
  • Gentherm Medicals
  • International Biomedical Ltd.
  • Global Health Care SG
  • Stryker Corporation
  • Aspen Systems (*LIST NOT EXHAUSTIVE)

第 12 章：附录

简介目录
Product Code: MD8605

Report Overview

The Global Therapeutic Hypothermia Market reached US$ 288 million in 2023 and is expected to reach US$ 458.11 million by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

Therapeutic hypothermia or temperature management is an active treatment that tries to achieve and maintain a specific body temperature in a person for a specific duration of time to improve health outcomes during recovery after a period of stopped blood flow to the brain. This is done in an attempt to reduce the risk of tissue injury following a lack of blood flow. Periods of poor blood flow may be due to cardiac arrest or the blockage of an artery by a clot as in the case of a stroke.

Beneficial effects of therapeutic hypothermia have also been discovered, and progress has been made toward improving the benefits of therapeutic hypothermia further through combination with other neuroprotective treatments and by probing the mechanism of hypothermia neuroprotection.

Market Dynamics: Drivers

Increasing prevalence of neurological and cardiovascular diseases

The demand for the global therapeutic hypothermia market is driven by multiple factors. The rising prevalence of neurological and cardiovascular diseases propels the market growth. For instance, according to the World Heart Federation.org, an article published on 20 May 2023, deaths due the cardiovascular diseases have increased from 12.1 million in 1990 to 20.5 million in recent times. The increase in air pollution, tobacco use, and increase in high blood pressure cases increased from deaths due to cardiovascular diseases in recent times.

According to an article posted on the World Health Organization website in March 2024, neurological diseases have increased by 18% in recent times, and over 1 in every 3 people are being affected by neurological disorders. It is estimated that more than 3 billion people are living with neurological diseases among the overall global population. Neurological conditions cause more disability and health loss in men compared to women, but there are some conditions like migraine or dementia where women are disproportionately affected.

Restraints

Factors such as the complexity involved in the procedures related to therapeutic hypothermia and stringent regulatory requirements are expected to hamper the market.

Market Segment Analysis

The global therapeutic hypothermia market is segmented based on product type, application, end-user, and region.

The segment neurology accounted for approximately 43.4% of the global therapeutic hypothermia market share

The neurology segment is expected to hold the largest market share over the forecast period. In this segment, the increase in the prevalence of neurological diseases and the increase in the usage of therapeutic hypothermia in this segment would drive this market.

According to nih.gov, therapeutic hypothermia was shown to be neuroprotective in both cardiac arrest patients and neonatal HIE patients, there is hope that it will similarly reduce morbidity and mortality following ischemic stroke. Indeed, a few preclinical studies showed that mild therapeutic hypothermia initiated during acute ischemic stroke or after a short delay reduced infarct size and mitigated functional impairment in a recent meta-analysis. In addition to these studies, another study showed feasibility and tolerability and established regimens to prevent or reduce shivering in the typically awake stroke patient.

For instance, in a recent multicenter study, an endovascular cooling device was used in combination with the administration of recombinant tissue plasminogen activator (rt-PA) in acute stroke patients. Here, patients could be treated within 0-6 h of symptom onset followed by endovascular cooling to 33oC for 24 h. While the study was not designed to evaluate the relative efficacy of therapeutic hypothermia, this regimen appeared well tolerated, although there was an increased incidence of pneumonia amongst cooled patients. A few clinical trials in ischemic stroke showed promising effects of therapeutic hypothermia.

Market Geographical Analysis

North America accounted for approximately 47.2% of the global therapeutic hypothermia market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of neurological and cardiovascular diseases, growing awareness among people about the benefits that are associated with therapeutic hypothermia, and the presence of major players in this region, help to propel the market.

For instance, according to an article posted by the Pan American Health Organization (PAHO) in March 2024, there have been 5,33,172 deaths due to various neurological disorders and conditions in the US. Among these 5,33,172 deaths, 2,13,129 were male and the remaining 3,20,043 were female. In the entire population of the US, there are 32.9 deaths per 100,000 population. In the men population, there are 33.1 deaths per 100,000 population, and in the female population, there are 32.2 deaths per 100,000 population.

Moreover, according to an article posted in May 2024 by cdc.gov, cardiovascular diseases are the leading cause of death among the population in the US. For every 33 seconds, one person is being dead due to cardiovascular disease. 1 in every 5 deaths is due to the cardiovascular disease. The increase in prevalence of neurological and cardiovascular diseases being the main driving factor is seen in the North American region which accounts for the largest market share.

Market Segmentation

By Product Type

  • Surface cooling packs
  • Surface heat exchange device
  • Surface cooling helmet
  • Catheter technology
  • Cold fluids infusion
  • Others

By Application

  • Neurology
  • Cardiology
  • Neo-natal care

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulance and Emergency Medical Service
  • Academic and Research Institutes
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the global therapeutic hypothermia market include Asahi Kasei Corporation, Becton Dickinson and Company, Shenzhen Comen Medical Instruments Co., Terumo Cardiovascular Systems Corporation, Phoenix Medical Systems, Gentherm Medicals, International Biomedical Ltd., Global Healthcare SG, Stryker Corporation, Aspen Systems among others.

Key Developments

  • In 2023, a medical device manufacturing company braincool which manufactures and offers therapeutic hypothermia systems signed an agreement with the Asahi Kasei Corporation, a Japan-based company for cooling systems and cooling pads for European and US markets.
  • In January 2024, SourceMark Medicals announced an expanded partnership with Gentherm Medicals. SourceMark is the master supplier of certain Gentherm patient warming product lines in the United States, including Astopad(R), a resistive warming system designed to prevent and treat hypothermia, Norm-O-Temp(R), a whole-body hyperthermia system, Gelli-Roll(R), a reusable warming and cooling gel pad, the WarmAir(R) convective patient warming system, and FilteredFlo(R) patient warming air blankets.
  • In March 2023, a company called NICE came into partnership with Aspen Group. This partnership leverages NICE's advanced cold compression technology with Aspen's effective bracing solutions to deliver pain management and post-operative care to patients recovering from surgery or injury. NICE therapy pads seamlessly attach to the market-leading Vista Cervical Collar and the Horizon 637, allowing patients to receive cold therapy pneumatic compression in an all-in-one, easy-to-use device. This reduces symptoms of swelling, assists with lymphatic drainage, and improves recovery outcomes.

Why Purchase the Report?

  • To visualize the global therapeutic hypothermia market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of global therapeutic hypothermia market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global therapeutic hypothermia market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Neurological and Cardiovascular Diseases
      • 4.1.1.2. Technological Advancements
      • 4.1.1.3. Increase in Awareness regarding the benefits of therapeutic hypothermi
    • 4.1.2. Restraints
      • 4.1.2.1. Complications involved in procedures
      • 4.1.2.2. Stringent Regulatory Requirements
  • 4.2. Opportunity
  • 4.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Surface Cooling Packs*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Surface Heat Exchange Device
  • 6.4. Surface Cooling Helmet
  • 6.5. Catheter Technology
  • 6.6. Cold Fluids Infusion
  • 6.7. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Neurology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cardiology
  • 7.4. Neo-natal Care

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Ambulance and Emergency Medical Services
  • 8.5. Academic and Research Institutes
  • 8.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. UK
      • 9.3.7.3. France
      • 9.3.7.4. Italy
      • 9.3.7.5. Spain
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Asahi Kasei Corporation *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Becton Dickinson and Company
  • 11.3. Shenzhen Comen Medical Instruments Co.
  • 11.4. Terumo Cardiovascular Systems Co.
  • 11.5. Phoenix Medical Systems
  • 11.6. Gentherm Medicals
  • 11.7. International Biomedical Ltd.
  • 11.8. Global Health Care SG
  • 11.9. Stryker Corporation
  • 11.10. Aspen Systems (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us